跳转至内容
Merck
  • Investigation of the therapeutic effectiveness of active components in Sini decoction by a comprehensive GC/LC-MS based metabolomics and network pharmacology approaches.

Investigation of the therapeutic effectiveness of active components in Sini decoction by a comprehensive GC/LC-MS based metabolomics and network pharmacology approaches.

Molecular bioSystems (2014-10-16)
Si Chen, Si Wu, Wuhong Li, Xiaofei Chen, Xin Dong, Guangguo Tan, Hai Zhang, Zhanying Hong, Zhenyu Zhu, Yifeng Chai
摘要

As a classical formula, Sini decoction (SND) has been fully proved to be clinically effective in treating doxorubicin (DOX)-induced cardiomyopathy. Current chemomics and pharmacology proved that the total alkaloids (TA), total gingerols (TG), total flavones and total saponins (TFS) are the major active ingredients of Aconitum carmichaelii, Zingiber officinale and Glycyrrhiza uralensis in SND respectively. Our animal experiments in this study demonstrated that the above active ingredients (TAGFS) were more effective than formulas formed by any one or two of the three individual components and nearly the same as SND. However, very little is known about the action mechanisms of TAGFS. Thus, this study aimed to use for the first time the combination of GC/LC-MS based metabolomics and network pharmacology for solving this problem. By metabolomics, it was found that TAGFS worked by regulating six primary pathways. Then, network pharmacology was applied to search for specific targets. 17 potential cardiovascular related targets were found through molecular docking, 11 of which were identified by references, which demonstrated the therapeutic effectiveness of TAGFS using network pharmacology. Among these targets, four targets, including phosphoinositide 3-kinase gamma, insulin receptor, ornithine aminotransferase and glucokinase, were involved in the TAGFS regulated pathways. Moreover, phosphoinositide 3-kinase gamma, insulin receptor and glucokinase were proved to be targets of active components in SND. In addition, our data indicated TA as the principal ingredient in the SND formula, whereas TG and TFS served as adjuvant ingredients. We therefore suggest that dissecting the mode of action of clinically effective formulae with the combination use of metabolomics and network pharmacology may be a good strategy.

材料
货号
品牌
产品描述

Sigma-Aldrich
丙酮, ACS reagent, ≥99.5%
Sigma-Aldrich
丙酮, suitable for HPLC, ≥99.9%
Sigma-Aldrich
丙酮, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
庚烷, suitable for HPLC, ≥99%
Sigma-Aldrich
吡啶, ACS reagent, ≥99.0%
Sigma-Aldrich
庚烷, ReagentPlus®, 99%
Sigma-Aldrich
丙酮, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
吡啶, suitable for HPLC, ≥99.9%
Sigma-Aldrich
庚烷, HPLC Plus, for HPLC, GC, and residue analysis, 99%
Sigma-Aldrich
三甲基氯硅烷, ≥98.0% (GC)
Sigma-Aldrich
丙酮, suitable for HPLC, ≥99.8%
Sigma-Aldrich
丙酮, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
吡啶, ReagentPlus®, ≥99%
Sigma-Aldrich
庚烷, puriss. p.a., reag. Ph. Eur., ≥99% n-heptane basis (GC)
Sigma-Aldrich
乙酸酐, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99% (GC)
Sigma-Aldrich
三甲基氯硅烷, purified by redistillation, ≥99%
Sigma-Aldrich
丙酮, ACS reagent, ≥99.5%
Sigma-Aldrich
甲氧胺 盐酸盐, 98%
USP
丙酮, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
一水肌酸, anhydrous
Sigma-Aldrich
吡啶, anhydrous, 99.8%
Sigma-Aldrich
丙酮, histological grade, ≥99.5%
Sigma-Aldrich
丙酮, JIS special grade, ≥99.5%
Sigma-Aldrich
乙酸酐, ReagentPlus®, ≥99%
Sigma-Aldrich
乙酸酐, 99.5%
Sigma-Aldrich
丙酮, puriss., meets analytical specification of Ph. Eur., BP, NF, ≥99% (GC)
Sigma-Aldrich
丙酮, natural, ≥97%
Sigma-Aldrich
吡啶, ≥99%
Sigma-Aldrich
吡啶, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.5% (GC)
Supelco
N -甲基-双(三氟乙酰胺), for GC derivatization, LiChropur, ≥97.0% (GC)